Skip to content
OpenCapital
Get started

Iovance Biotherapeutics, Inc. IOVA Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$60.0MMiss by $18.4M
EPS-$0.33Miss by $0.04
Revenue estimate$78.3M
EPS estimate-$0.29

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$87.7M
EPS estimate-$0.17

Financials

Q2 2025

Income statement

See full
Revenue$60.0M+92.7%
Gross profit$3.3M+1,355%
Operating income-$113.8M-11.6%
Net income-$111.7M-15.0%
EPS (diluted)-$0.33+2.9%

Balance sheet

See full
Cash & equivalents$132.5M-43.7%
Total debt$52.2M-36.1%
Total equity$698.5M-9.1%
Total assets$907.4M-5.9%

Cash flow

See full
Operating cash flow-$67.4M+31.5%
CapEx$7.5M+1,588%
Free cash flow-$74.9M+24.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$627.8M-70.6%
Enterprise value$547.49M-72.4%
P/S2.6×-62.6×

Profitability

See full
Gross margin30.2%+22.7pp
Operating margin-170%-79.5pp
Net margin-161.4%-75.6pp
FCF margin-134%-63.1pp

Returns & leverage

See full
Return on equity-53.2%-8.4pp
Debt / equity0.1×0.0×
Current ratio3.3×-1.9×

Segments

By product

See full
Amtagvi$54.1M+322%
Proleukin$5.9M-67.9%

By segment

See full
Single Reportable$60.0M+92.7%

Versus estimates

Revenue

Q1 2026$71.4MMiss by $6.4MQ4 2025$86.7MBeat by $6.0MQ3 2025$67.5MMiss by $14.7M
Q2 2025$60.0MMiss by $18.4M
Q1 2025$49.3MMiss by $33.1MQ4 2024$73.7MBeat by $1.5M

Diluted EPS

Q1 2026-$0.19In lineQ4 2025-$0.18Beat by $0.04Q3 2025-$0.25Beat by $0.04
Q2 2025-$0.33Miss by $0.04
Q1 2025-$0.36Miss by $0.11Q4 2024-$0.26In line

Ask the moment Iovance Biotherapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Iovance Biotherapeutics, Inc. report Q2 2025 earnings?
Iovance Biotherapeutics, Inc. (IOVA) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Iovance Biotherapeutics, Inc.'s Q2 2025 revenue and EPS?
Iovance Biotherapeutics, Inc. reported revenue of $60.0M and eps of $-0.33 for Q2 2025.
Did Iovance Biotherapeutics, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $78.3M by $18.4M. EPS missed the consensus estimate of $-0.29 by $0.04.
How did Iovance Biotherapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 92.7% from $31.1M a year earlier and eps grew 2.9% from $-0.34.
Where can I find Iovance Biotherapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001558370-25-010807) directly on SEC EDGAR. The filing index links above go to sec.gov.